Monte Rosa Therapeutics, Inc. (GLUE)

Market Cap	267.32M
Revenue (ttm)	n/a
Net Income (ttm)	-135.35M
Shares Out	50.15M
EPS (ttm)	-2.63
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	86,169
Open	5.37
Previous Close	5.45
Day's Range	5.29 - 5.50
52-Week Range	2.44 - 8.84
Beta	1.45
Analysts	Buy
Price Target	11.00 (+106.38%)
Earnings Date	May 9, 2024

About GLUE

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1"/NLRP...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 24, 2021
• Employees: 133
• Stock Exchange: NASDAQ
• Ticker Symbol: GLUE

Analyst Forecast

According to 3 analysts, the average rating for GLUE stock is "Buy." The 12-month stock price forecast is $11.0, which is an increase of 106.38% from the latest price.

Price Target

$11.0

(106.38% upside)

Analyst Consensus: Buy